1. Home
  2. PLSE vs CRNX Comparison

PLSE vs CRNX Comparison

Compare PLSE & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$54.70

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$84.97

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
CRNX
Founded
2014
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.9B
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
PLSE
CRNX
Price
$54.70
$84.97
Analyst Decision
Buy
Strong Buy
Analyst Count
1
8
Target Price
$22.00
$76.75
AVG Volume (30 Days)
470.4K
2.4M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,039,000.00
Revenue This Year
$840.00
$720.10
Revenue Next Year
$287.54
$184.67
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$32.30
52 Week High
$54.39
$85.01

Technical Indicators

Market Signals
Indicator
PLSE
CRNX
Relative Strength Index (RSI) 78.33 89.88
Support Level $24.27 $83.47
Resistance Level N/A N/A
Average True Range (ATR) 2.90 0.12
MACD 0.08 -0.86
Stochastic Oscillator 91.40 93.85

Price Performance

Historical Comparison
PLSE
CRNX

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: